SCHEMBL1349263

SCHEMBL1349263

NC(C(=O)O)c1c[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 3/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.56
MPO P05164 1/20 0.56
TSHR P16473 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
HIF1A Q16665 1/20 0.56
PKM P14618 1/20 0.56
GPR84 Q9NQS5 4/20 0.53
MGAM O43451 3/20 0.52
GAA P10253 3/20 0.52
SI P14410 3/20 0.52
MGAM2 Q2M2H8 3/20 0.52
FFAR1 O14842 2/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR2B P41595 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10079616 1.00 MEN1 (0.56) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL30518932 1.00 MEN1 (0.56) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL30518090 1.00 MEN1 (0.56) MEN1KMT2AMAPTKDM4ELMNA
Hydrochloric Acid SCHEMBL11187822 0.98 MEN1 (0.55) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL2870565 0.86 ALDH1A1 (0.54) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL8234032 0.85 GPR84 (0.53) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL10821238 0.85 HTR2A (0.49) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL10332616 0.85 HTR2A (0.49) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL4170824 0.83 MAPT (0.54) MEN1KMT2AMAPTKDM4ELMNA
SCHEMBL4184199 0.83 MAPT (0.54) MEN1KMT2AMAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465660-B2 Compositions and methods for cancer imaging and radiotherapy VECT-HORUS (FR) 2025-11-11 US disclosed
US-20240100204-A1 COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY VECT-HORUS (FR) 2024-03-28 US disclosed
US-11712486-B2 Compositions and methods for cancer imaging and radiotherapy VECT-HORUS (FR) 2023-08-01 US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 US disclosed
CN-110452151-B Synthetic method of alpha-indole glycine derivative 江苏科技大学 2022-12-30 CN disclosed
US-20190351079-A1 COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY VECT-HORUS (FR) 2019-11-21 US disclosed
EP-2908837-B1 COMPOSITIONS FOR DRUG DELIVERY VECT HORUS (FR) 2019-02-13 EP disclosed
WO-2018138372-A1 COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY VECT-HORUS (FR) 2018-08-02 WO disclosed
EP-2547692-B1 PEPTIDE DERIVATIVES, PREPARATION THEREOF AND USES THEREOF AS VECTORS VECT-HORUS (FR) 2017-05-17 EP disclosed
US-5245046-A α-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1993-09-14 US disclosed
EP-0375133-A1 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1990-06-27 EP disclosed
EP-0375133-A1 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1990-06-27 EP disclosed
EP-0375133-A1 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents THE UPJOHN COMPANY (US) 1990-06-27 EP disclosed
WO-1990005721-A1 ALPHA-AMINO-INDOLE-3-ACETIC ACIDS USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS THE UPJOHN COMPANY (US) 1990-05-31 WO disclosed
WO-1990005721-A1 ALPHA-AMINO-INDOLE-3-ACETIC ACIDS USEFUL AS ANTI-DIABETIC, ANTI-OBESITY AND ANTI-ATHEROSCLEROTIC AGENTS THE UPJOHN COMPANY (US) 1990-05-31 WO disclosed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US disclosed
EP-0073143-B1 NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES Ryan, James Walter (US) 1985-11-21 EP disclosed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP MEN1 58/4885KMT2A 1875/4885MAPT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.